Introduction
Prior to neoplastic transformation, initiated normal cells undergo a re-programming of inherent gene expression, permitting subsequent cancer promotion and progression. These changes typically result in upregulation of proteins that provide pro-survival signals and downregulation of cell-death initiation events. One prosurvival pathway commonly and constitutively upregulated in human tumors is the insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) tyrosine kinase signaling cascade (Ryan and Goss, 2008) . We found that exposure of cells to IGF-1 induced secretory clusterin (sCLU) expression, and that IGF-1R signaling was essential for sCLU upregulation after ionizing radiation (IR) exposure. In addition to IR, sCLU was induced after exposure to chemotherapeutic agents and ultraviolet (UV) radiation (Boothman et al., 1993; Miyake et al., 2000) ; however, the role of IGF-1/IGF-1R signaling in sCLU induction after these agents was not investigated. Although we noted that wild-type p53 repressed basal sCLU expression and partially inhibited sCLU upregulation after IR exposure (Criswell et al., 2003) , a link between IGF-1R signaling and p53 suppression was not elucidated. The initiating signals from DNA damage to upregulation of IGF-1/IGF-1R signaling also remain undefined.
sCLU is a heavily glycosylated, 80 kDa secreted protein that functions in both an extra-and intracellular manner to promote cell survival. sCLU is synthesized as a 60-kDa precursor protein (psCLU) that is targeted to the ER. Within the ER, psCLU is cleaved approximately into half, linked together by five disulfide bonds, and is heavily glycosylated to form mature sCLU (80 kDa) . sCLU production appears as two major protein forms by western blotting. The band at B60 kDa corresponds to psCLU and represents the protein before maturation. The B40-kDa smear corre-sponds to one half of the mature sCLU at varying states of glycosylation (Jones and Jomary, 2002) . Expression changes in psCLU and sCLU are always concordant, and both forms consistently match CLU promoter activity (Criswell et al., 2003) , allowing any one of these forms to be monitored for changes in sCLU expression.
Outside the cell, sCLU acts as a molecular chaperone, binding to stress-induced unfolded proteins, lipids and amyloid, among other molecules, and works to clear cell debris after tissue trauma (de Silva et al., 1990; Boggs et al., 1996; Wilson and Easterbrook-Smith, 2000) . Within the cell, sCLU can bind Bax and prevent its translocation to the mitochondria, thereby blocking apoptosis (Zhang et al., 2005) . Due to its pro-survival functions, sCLU overexpression is partially responsible for increased resistance of cancer cells to various stresses, including doxorubicin, cisplatin and taxol (Miyake et al., 2000) . Depletion of sCLU by antisense or small interfering RNA caused hypersensitization of cancer cells to paclitaxel or IR (Criswell et al., 2005; So et al., 2005) . Aside from exogenous stress, sCLU is constitutively elevated in many early-stage cancers, during replicative senescence, and in Alzheimer's disease (Chen et al., 2003) . These observations strongly suggest that elevated sCLU levels in cancer, as well as induction of sCLU after cytotoxic agent exposures, may result in the consequent resistance of cancer cells to therapy, including cancer stem cells. Therefore, antisense constructs specific for sCLU (for example, OGX-011) were developed and are now in phase II/III clinical trials in combination with standard chemotherapies for prostate cancer (Chi et al., 2010) . Thus, understanding sCLU regulation after DNA damage and in genetically unstable cells should lead to a better understanding of resistance to therapy and open avenues for improving cancer therapy.
Here, we show that p53 and NF-YA are necessary to suppress basal IGF-1 transcription by binding together at a single NF-Y consensus site within the IGF-1 promoter. Although p53 levels were stabilized and elevated after IR exposure, loss of p53/NF-YA binding from the IGF-1 promoter after IR exposure allows for IGF-1 induction to, in turn, activate IGF-1R signaling and sCLU induction. Interestingly, we noted that genetically unstable cells have heightened basal IGF-1 and sCLU levels and concomitant elevated Ataxia telangiectasia-mutated kinase (ATM) signaling, not unlike cells undergoing a DNA damage response. We found that ATM was the DNA damage sensor kinase responsible for IGF-1-sCLU upregulation after endogenous or exogenous DNA damage. Collectively, our findings show that the ATM-IGF-1-sCLU expression axis is an important pro-survival pathway activated in response DNA damage, which has important implications in carcinogenesis, tumor progression and resistance in cancer therapies.
Results
p53 negatively regulates basal IGF-1 expression p53 has an important and essential role in responding to cell stress by either activating or repressing gene expression, controlling checkpoint responses, and inducing apoptosis. Data from our laboratory suggested that p53 suppressed basal sCLU expression; however, sCLU was moderately induced after IR exposure, even though p53 was stabilized (Criswell et al., 2003) . The mechanism of p53-mediated repression of basal sCLU expression was not explored. Since prior data suggested that IGF-1 signaling may regulate sCLU expression (Criswell et al., 2005) and p53 was regulated, through Mdm-2 expression, by IGF-1 (Mayo and Donner, 2001) , we examined the ability of p53 to regulate IGF-1 transcription. To test this, the IGF-1 promoter fused to luciferase reporter (IGF-1-LUC) (Mittanck et al., 1997) was transfected into a series of genetically matched cell lines altered in functional p53 (Figure 1a ). p53-null (PC3 and HCT116 p53 À/À ) and p53 knockdown (RKO7 shp53, HCT116:3-6 shp53, HBEC 3kt shp53) cells had higher basal IGF-1 promoter activity compared with matched WT p53-expressing cells (white bars; PC3 (stably expressing WT p53), RKO7 SCR, HCT116 SCR, HCT116:3-6 SCR and HBEC 3kt). Immortalized human bronchial epithelial (HBEC 3kt, WT p53) cells expressing mutant R273H p53 (mp53) also had elevated basal IGF-1 promoter activity. Similarly, IGF-1 mRNA and protein expression was higher in HCT116:3-6 shp53 compared with SCR cells (Figures 1b and c) . These data suggested that p53 transcriptionally repressed basal IGF-1 in a dosedependent manner, as complete loss of functional p53 allowed for greater IGF-1 expression than in cells where p53 was knocked down.
Since IGF-1R signaling was activated by IR exposure (Criswell et al., 2005) , we examined whether IGF-1 was elevated after IR treatment, and if its expression was dependent on p53 status. In RKO7 SCR and shp53 cells, IGF-1 protein and promoter activity were induced in both cell lines after IR exposure. However, IGF-1 was induced to a significantly greater extent when p53 was knocked down (Figures 1d and e) . These data strongly suggested that p53 transcriptionally repressed basal IGF-1 expression, while only partially blocking IR-induced IGF-1. These data also suggested that the p53 repression mechanism of IGF-1 (and sCLU) was fundamentally different than other p53 targets, such as Chk2, since Chk2 is further suppressed after IR exposure due to stabilization of p53 (Matsui et al., 2004) .
p53 and NF-Y-mediated transcriptional regulation of IGF-1 Since IGF-1 was induced in WT p53 cells after IR exposure even though p53 was stabilized, we investigated the mechanism of p53 suppression, and whether this changed after IR. Interrogation of the human IGF-1 promoter for potential regulatory elements repressed by p53 led to the identification of a single NF-Y consensus site found at À438 bp in the IGF-1 promoter (Figure 2a in HCT116 cells resulted in modest repression of the IGF-1 promoter; however, NF-YA was not able to suppress in the absence of p53 (HCT116 p53 Figure 2c ), consistent with studies showing that NF-YA mediates the interaction between p53 and DNA (Imbriano et al., 2005) . Finally, chromatin immunoprecipitation analyses were performed to examine the binding of p53 and NF-YA, -YB or -YC to the IGF-1 promoter. After IR exposure, p53 protein levels were stabilized ( Figure 2d) ; however, p53 and NF-YA binding to the IGF-1 promoter decreased. NF-YB and NF-YC binding increased 72 h after IR exposure (Figure 2e ). Intriguingly, NF-YB binding to the IGF-1 promoter decreased 6 h after IR exposure; however, as IGF-1 and sCLU are most robustly induced 48-72 h after IR exposure, decreased binding at 6 h may not affect IGF-1 expression. As a positive control, increased p53 binding to the p21 promoter was noted after IR exposure ( Figure 2e ). These data suggest that IGF-1 induction after IR exposure in WT p53 cells was due to loss of p53 and NF-YA occupancy on the IGF-1 promoter, and thereby loss of repression. These data strongly suggested that NF-YA is rate limiting and p53 alone is not capable of repressing IGF-1.
p53 suppression of the IGF-1-sCLU pathway To show that IGF-1 signaling was upstream of sCLU expression, cells were treated with AG1024, an IGF-1R tyrosine kinase inhibitor, before IR exposure. AG1024 blocked IR-induced CLU promoter activity in RKO7 shp53 cells, while having no effect on IGF-1 promoter induction (Figure 3a) . The overall lower induction of IGF-1 and CLU promoter activity observed in the WT p53 RKO7 cells was probably due to the low serum conditions required for AG1024 efficacy. To determine if both IGF-1 and CLU expression were similarly regulated by p53, HCT116 and HCT116 p53 À/À cells were transiently transfected with WT flag-tagged p53 cDNA (WT p53) and IGF-1-or CLU-LUC reporters before IR exposure. Basal IGF-1 and CLU promoter activities were significantly higher in HCT116 p53 À/À cells compared with WT p53 cells (Figure 3b ), consistent with previous results. Overexpression of non-lethal p53 levels partially blocked IR-induced IGF-1 and CLU promoter activities in both cell lines (Figure 3b ). CLU and IGF-1 promoter activities and sCLU protein induction after IR exposure were also partially blocked by p53 in RKO7 cells (Supplementary Figures S1A-C) . Since both IGF-1 and CLU were similarly regulated by p53, an inter-dependent relationship between the expression patterns of these two genes was revealed, showing that upstream IGF-1 expression directly controlled sCLU synthesis.
Induction of sCLU by DNA damage Since IGF-1R signaling was required for sCLU induction after IR exposure, we examined whether this pathway was activated after other forms of DNA damage. In RKO7 cells, induction of both the intracellular, B60-kDa precursor sCLU (psCLU) and the B80-kDa mature sCLU (appearing as an B40-kDa smear) were noted after exposure to IR, H 2 O 2 or topoisomerase I or IIa poisons, topotecan (TPT) or VP16, respectively (Figures 4a and c) . Induction of sCLU was inhibited by AG1024 pre-treatment (Figure 4a ). IGF-1 expression and phosphorylation of ERK were observed after DNA damage (Figure 4b and Supplementary Figures S2A-C) , consistent with IGF-1R-mitogen-activated protein kinase (MAPK) activation after IR exposure (Criswell et al., 2005) . These data suggested a common DNA damage-induced pathway of IGF-1 induction that activated IGF-1R-MAPK signaling, leading to sCLU expression.
To determine whether DNA double-strand breaks (DSBs) were necessary for sCLU induction, cells were exposed to aphidicolin (Aph), a DNA polymerase (Figures 4c and d) . In contrast, Aph did not affect sCLU induction for the agents that directly caused DSBs. These data suggested that DSBs were minimally sufficient to induce sCLU.
The IGF-1-sCLU expression axis is upregulated in genetically unstable cells Noting that DSBs were minimally required for IGF-1-sCLU expression (Figures 4c and d) and that genetically unstable cells commonly exhibit constitutive DSBs, we examined whether genetic instability, in general, led to an increase in sCLU expression. Various genetically unstable cells were examined for IGF-1 and sCLU expression compared to stable, genetically matched cells (Figures 5a and b) . Cells deficient in H2AX (H2AX À/À ) have defective localization of BRCA1 and 53BP1, deficiencies in homologous recombination and persistent DSBs (Celeste et al., 2002) . Elevated basal expression of sCLU was noted in H2AX À/À MEFs compared to genetically matched and stable, WT MEFs. Similarly, sCLU expression was constitutively elevated in MDC1 À/À MEFs, which have defects in ATM recruitment (but not activation), leading to increased DSBs and genetic instability (Lou et al., 2006) . sCLU expression was also elevated in fifth generation MEFs defective for the RNA component of mouse telomerase, mTR ( Figure 5a) ; mTR À/À MEFs are genetically unstable due to a failure to extend telomere ends, revealing DSBs that lead to chromosomal rearrangements and end-to-end fusions (Hao and Greider, 2004 (Figure 5b ). We then examined whether IGF-1 signaling was elevated in cells with endogenous genetic instability. Elevated IGF-1 and CLU promoter activity was noted in H2AX À/À MEFs, compared with WT control cells (Figure 5c ). Higher levels of intracellular IGF-1 in H2AX À/À MEFs were noted (Supplementary Figure  S2D) , with constitutively elevated basal phosphorylation of IGF-1R, AKT1 and ERK (Figure 5d and Supplementary Figure S2E Figures  S2F and G) , suggesting that IGF-1/IGF-1R signaling was constitutively active in unstable cells, leading to sCLU expression. These data strongly suggested that the same IGF-1/IGF-1R/MAPK/ERK signaling pathway that was activated after exogenous DNA damage was responsible for stimulating basal sCLU expression in genetically unstable cells. sCLU induction following DNA damage is mediated by ATM Since IGF-1-sCLU expression was elevated in response to DNA damage, we wanted to delineate the DNA damage sensor responsible for upregulating this expression axis. Since ATM and ATR signaling are activated in response to the DNA-damaging agents used, we suspected that these two PIKKs might be involved in IGF-1-sCLU expression. Genetically unstable MEFs were examined for upregulation of ATM signaling by analyzing phosphorylation of H2AX (g-H2AX) and auto-activation of ATM (phosphorylation of S1981). Neither H2AX À/À nor MDC1 À/À MEFs showed g-H2AX staining due to their known abrogation of this response (Lou et al., 2006) , but had elevated basal pATM S1981 levels (Figures 5f and g ). WT MEFs were responsive to IR exposure, showing elevated pATM S1981 and g-H2AX staining (Figures 5f and g ). Additionally, both pATM S1981 and g-H2AX were elevated in RKO7 cells exposed to TPT, which were abrogated by Aph pretreatment (Supplementary Figure S3A) . ATR signaling, as determined by Chk1 phosphorylation on serines 317 and 345, was elevated in H2AX-, MDC1-and mTRdeficient cells (Supplementary Figure S3B) . These data suggested that both ATM and ATR signaling were elevated under the same conditions in which IGF-1-sCLU expression was upregulated.
The requirement for ATM or ATR activation in IGF-1/sCLU expression was examined by pre-treating cells with AAI, a dual ATM and ATR kinase inhibitor (see Bentle et al., 2006) . AAI blocked pATM S1981 and g-H2AX staining in irradiated MEF and human cells (Supplementary Figures S4A and B) , and lowered basal sCLU protein expression in genetically unstable cells (Figure 6a ). AAI also prevented sCLU induction in MCF-7 cells following IR or TPT exposure (Figure 6b) . Thus, either ATM or ATR were possible DNA damage sensor kinases directing IGF-1-sCLU induction.
To delineate between ATM and ATR, sCLU induction was examined in genetically defined, SV-40 immortalized AT fibroblasts (ATM À/À ) compared with genetically matched, ATM-reconstituted AT fibroblasts (ATM þ /À ). Although ATM À/À cells are genetically unstable (Kojis et al., 1991) and sensitive to IR (Ziv et al., 1997) , sCLU basal expression was equal to ATMcorrected (ATM þ /À ) fibroblasts (Figures 6c and e , and Supplementary Figure S5A) , presumably due to the presence of IGF-1 in the culture medium. Importantly, þ / þ MEFs were treated with AG1024 (2 mM) and collected 48 h later. (f, g) H2AX (f) or MDC1 (g) WT ( þ / þ ) or deficient (À/À) MEFs were analyzed for pATM S1981 and g-H2AX levels 1 h after 5 Gy by flow cytometry. For (c, f, g), data were graphed as means ± s.d. *Pp0.05. RL, relative levels; RLU, relative light units.
ATM
À/À fibroblasts did not induce sCLU after IR exposure, unlike ATM þ /À fibroblasts (Figure 6c ). Similarly, sCLU expression was not induced in GM2052 primary AT fibroblasts after IR exposure ( Figure 6d) . As an important control, both ATM À/À and ATM þ /À fibroblasts were able to induce sCLU and showed phosphorylation of IGF-1R and AKT1 by exogenous IGF-1 (Supplementary Figures S5A and B) , indicating that both cell lines were proficient in IGF-1-sCLU expression, but not in signaling from DNA damage to sCLU induction. The possible role of ATR signaling in IGF-1-sCLU expression was examined by exposing ATM À/À and ATM þ /À fibroblasts to UV (1 or 3 J/m 2 ), which predominately activates ATR. Similar to IR, sCLU induction was observed only in ATM þ /À cells after UV treatment (Figure 6e) , probably due to ATR-dependent activation of ATM after UV exposure (Stiff et al., 2006) . As a control, p53-mediated DNA damage-inducible expression of the human homolog of Mdm2 was noted in both ATM À/À and ATM þ /À cells after UV exposure (Figure 6e) (Perry et al., 1993) . Also, Chk1 S317 phosphorylation in UV-irradiated ATM À/À and ATM þ /À cells was noted (Figure 6e and Supplementary Figure  S5C ), confirming ATR activation (Zhao and PiwnicaWorms, 2001 ). These data strongly suggested that ATM, and not ATR, was necessary for sCLU induction after IR exposure. Since p53 and NF-YA binding to the IGF-1 promoter were lost after IR exposure in HCT116 cells, p53/NF-YA binding was examined in ATM þ /À vs ATM À/À cells before and after IR. As in HCT116 cells (Figure 2e) , both p53 and NF-YA were lost from the IGF-1 promoter after IR exposure in ATM þ /À , although no change was detected in ATM À/À cells (Figure 6f ). These data strongly suggested that ATM signaling was important for loss of NF-YA and p53 from the IGF-1 promoter after IR exposure, alterations required for IGF-1-sCLU upregulation in response to DNA damage.
Since ATM and ATM-activated proteins (for example, activated Chk2) phosphorylate p53 at serines 15 and 20 after IR exposure, we examined whether these post-translational modifications of p53 altered its ability to repress IGF-1 or sCLU. HCT116 p53 À/À cells were transiently transfected with WT p53, or p53 constructs containing serine 15 or 20 mutated to non-phosphorylated alanine mutants (S15A, S20A), or the phospho-mimic aspartate (S15D) or glutamate mutants (S15E, S20E). All serine 15 and 20 mutants repressed IGF-1 and CLU promoter activities similar to WT p53 (Supplementary Figures S5D and E) , even though these are obvious direct and indirect targets of ATM kinase activity after DNA damage. As a positive control, the p21 promoter (el-Deiry et al., 1993) was induced by WT and to a lesser extent by S15A, S15E and S20A p53 mutants (Supplementary Figure S5F ) (Dumaz and Meek, 1999) . Mutation of S20 to glutamate enhanced p53-mediated activation of the p21 promoter over WT. Additionally, mutation of p53 at S20 blocked the ability of the DO1 p53 antibody to detect p53 (Supplementary Figure S5F, right) . Thus, our data strongly suggested that activation of ATM signaling, and not ATR, was sufficient to induce IGF-1-sCLU expression, a common damage-inducible pro-survival expression axis initiated by genotoxic stress or genetic instability.
Discussion
Genetic instability is a hallmark of cancer initiation, triggering changes that induce a switch from normal to uncontrolled growth. Engagement of survival pathways within these aberrant cells is important for cancer promotion and progression. Our results integrate a novel signaling pathway, initiating from ATM, that activates the pro-survival IGF-1-sCLU axis due to endogenous or exogenous DNA damage (Figure 6g ). All cytotoxic agents that induced DSBs and activated ATM kinase led to IGF-1 induction and subsequent activation of IGF-1R, leading to sCLU expression. In normal cells, transient upregulation of IGF-1-sCLU expression after DNA damage is most likely beneficial, blocking apoptosis, providing a mitogenic stimulus and mobilizing glucose utilization to maintain cellular homeostasis until DNA repair is concluded. When this pathway is uncontrolled, however, like in genetically unstable cells or by loss of p53 function, IGF-1-sCLU upregulation may promote resistance of tumors to IR or chemotherapies and allow initiated cells to progress.
Several studies have suggested links between ATM, p53 and IGF-1 signaling, but this is the first report to show that p53, in conjunction with NF-YA, directly suppresses the IGF-1 promoter (Figures 6f and g ). Other studies suggested that p53 suppressed IGF-1; however, no mechanistic data were provided (Bocchetta et al., 2008; Sulkowski et al., 2009) . Additionally, ATM upregulates IGF-1R expression, and loss of IGF-1R, in turn, blocks ATM activation after IR exposure (Macaulay et al., 2001; Shahrabani-Gargir et al., 2004) . These observations appear to explain the biphasic activation of IGF-1R-MAPK signaling observed in MCF-7 cells after IR exposure (Criswell et al., 2005) . Initial IGF-1 signaling by ATM activation could trigger a more robust positive feedback loop, wherein IRinduced IGF-1 signaling activates AKT1. AKT1 stimulation then leads to p53 degradation via activation of Mdm2 (Leri et al., 1999) , resulting in robust but delayed synthesis of IGF-1 and sCLU. This may also explain the slower kinetics of IGF-1 induction in RKO7 SCR cells, compared with RKO7 shp53 cells, because the RKO7 shp53 cells already have lowered p53 (Figure 1e) .
NF-Y A-C proteins bind p53 and suppress transcription of target genes involved in cell cycle regulation, such as Cdc2 and Chk2 (Yun et al., 1999; Matsui et al., 2004) . These genes are suppressed after DNA damage by p53 stabilization (Matsui et al., 2004) . In contrast, IGF-1-sCLU expression was induced after low-(X2 cGy) and high-dose IR exposures, even though p53 was stabilized (Klokov et al., 2004) . This was concomitant with the simultaneous loss of NF-YA and p53 binding to the IGF-1 promoter. NF-YB and NF-YC binding increased after IR exposure (Figure 2e ), consistent with their abilities to bind TFIID independently of NF-YA and promote transcription (Bellorini et al., 1997) . Even though the mechanism of IGF-1 suppression by p53 and NF-YA is different from other known targets, it is not incongruous with the known functions of the NF-Y subunits.
Since we uncovered a novel mechanism of p53/ NF-YA-mediated suppression of IGF-1 transcription, we propose several possibilities for this loss of suppression after IR exposure, including post-translational modification of NF-YA and/or p53. Cdk2 phosphorylates NF-YA, and mutation of these sites blocked its ability to bind DNA (Yun et al., 2003) . We propose a model whereby Cdk2 promotes NF-YA phosphorylation in the basal state, enhancing p53/NF-YA binding to DNA and repressing IGF-1 promoter transactivation. After IR exposure, ATM-mediated p53 stabilization promotes p21 expression. p21, in turn, suppresses Cdk2, blocking NF-YA phosphorylation and releasing NF-YA from the IGF-1 promoter (Figures 2e and 6f) . Additionally, acetylation, phosphorylation or other post-translational modifications of p53 may have an impact on its ability to bind NF-YA and repress IGF-1 transcription. Studies to elucidate the roles of NF-YA and p53 post-translational modifications are ongoing. Collectively, our data indicate that ATM signaling results in NF-YA modification to prevent or reverse its binding to the IGF-1 promoter, suggesting that NF-YA is rate-limiting and cells retain the ability to induce IGF-1 expression and downstream sCLU production after IR exposure, even though p53 is stabilized. p53 null cells, or cells with p53 knockdown, induced IGF-1-sCLU to a much greater extent after IR exposure compared with WT p53 cells. These data suggest that a positive transcription factor, in addition to loss of p53/ NF-YA from the IGF-1 promoter, is required for IGF-1 induction. There are several candidate factors, including NF-YB/-YC itself, AIB1 or TGFb1 signaling, that may regulate IGF-1 expression. NF-Y is a known IRactivated transcription factor (Peng et al., 2007) , and NF-YB/-YC complexes may act as positive transcription factors for IGF-1 induction after IR exposure, consistent with increased NF-YB/-YC binding to the IGF-1 promoter (Figure 2e ). On the other hand, levels of the steroid receptor coactivator, AIB1, are directly correlated with IGF-1 expression (Wang et al., 2000) . AIB1 binds to the IGF-1 promoter with AP-1 (Yan et al., 2006) , suggesting that changes in these complexes may regulate IGF-1 expression after IR exposure. Finally, since TGFb1 induces sCLU (Jin and Howe, 1997) and TGFb1 signaling can be activated after IR exposure (Andarawewa et al., 2007) , TGFb1 signaling may be involved in IR-induced IGF-1 expression. Current studies are ongoing in our lab to elucidate the positive factors in induction of IGF-1 after DNA damaging agents.
In conclusion, we elucidated the complete signaling pathway from DNA damage to sCLU expression. By determining the signaling pathways involved in IGF-1-sCLU upregulation, important targets for anti-tumor therapy emerge, as well as the possibility of using IGF-1 and sCLU as markers for genetic instability and cancer progression.
